CYCN Cyclerion Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CYCN

Price (delayed)

$4.35

Market cap

$9.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.4

Enterprise value

$2.3M

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates ...

Highlights
Cyclerion Therapeutics's EPS has increased by 30% YoY and by 14% from the previous quarter
The net income rose by 26% year-on-year and by 14% since the previous quarter
The equity has plunged by 89% YoY and by 62% from the previous quarter
The company's gross profit has shrunk by 80% YoY and by 44% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cyclerion.com
Peers: OVID

Key stats

What are the main financial stats of CYCN
Market
Shares outstanding
2.18M
Market cap
$9.47M
Enterprise value
$2.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
Earnings
Revenue
$914,000
EBIT
-$38.43M
EBITDA
-$38.41M
Free cash flow
-$33.99M
Per share
EPS
-$17.4
Free cash flow per share
-$15.62
Book value per share
$1.8
Revenue per share
$0.42
TBVPS
$5.26
Balance sheet
Total assets
$11.46M
Total liabilities
$7.53M
Debt
$0
Equity
$3.93M
Working capital
$804,000
Liquidity
Debt to equity
0
Current ratio
1.11
Quick ratio
0.96
Net debt/EBITDA
0.19
Margins
EBITDA margin
-4,202.7%
Gross margin
100%
Net margin
-4,163.5%
Operating margin
-4,204.6%
Efficiency
Return on assets
-169.5%
Return on equity
-270.5%
Return on invested capital
N/A
Return on capital employed
-979.1%
Return on sales
-4,204.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYCN stock price

How has the Cyclerion Therapeutics stock price performed over time
Intraday
0%
1 week
6.62%
1 month
-95.8%
1 year
-98.19%
YTD
-98.34%
QTD
-97.49%

Financial performance

How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$914,000
Gross profit
$914,000
Operating income
-$38.43M
Net income
-$38.05M
Gross margin
100%
Net margin
-4,163.5%
The company's gross profit has shrunk by 80% YoY and by 44% QoQ
The revenue has dropped by 80% year-on-year and by 44% since the previous quarter
Cyclerion Therapeutics's operating margin has plunged by 54% from the previous quarter
Cyclerion Therapeutics's net margin has plunged by 53% from the previous quarter

Growth

What is Cyclerion Therapeutics's growth rate over time

Valuation

What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
2.41
P/S
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
Cyclerion Therapeutics's EPS has increased by 30% YoY and by 14% from the previous quarter
The equity has plunged by 89% YoY and by 62% from the previous quarter
The stock's price to book (P/B) is 15% more than its 5-year quarterly average of 2.1 but 11% less than its last 4 quarters average of 2.7
The revenue has dropped by 80% year-on-year and by 44% since the previous quarter
CYCN's P/S is 77% below its 5-year quarterly average of 44.5 and 45% below its last 4 quarters average of 18.7

Efficiency

How efficient is Cyclerion Therapeutics business performance
The company's return on equity has shrunk by 173% YoY and by 37% QoQ
CYCN's return on assets has dropped by 106% year-on-year and by 20% since the previous quarter
Cyclerion Therapeutics's ROS has plunged by 54% from the previous quarter

Dividends

What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYCN.

Financial health

How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total assets is 52% more than its total liabilities
The quick ratio has plunged by 78% YoY and by 46% from the previous quarter
The current ratio has plunged by 75% YoY and by 43% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has plunged by 89% YoY and by 62% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.